Koss Olinger Consulting LLC Buys 765 Shares of Johnson & Johnson (NYSE:JNJ)

Koss Olinger Consulting LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 16.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 5,434 shares of the company’s stock after buying an additional 765 shares during the quarter. Koss Olinger Consulting LLC’s holdings in Johnson & Johnson were worth $881,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Violich Capital Management Inc. lifted its position in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Violich Capital Management Inc. now owns 97,678 shares of the company’s stock worth $15,830,000 after purchasing an additional 557 shares during the period. Penn Davis Mcfarland Inc. purchased a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $6,807,000. One Degree Advisors Inc purchased a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $244,000. McClarren Financial Advisors Inc. lifted its position in shares of Johnson & Johnson by 12.6% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 1,152 shares of the company’s stock worth $187,000 after purchasing an additional 129 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its position in Johnson & Johnson by 0.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 451,598 shares of the company’s stock valued at $73,186,000 after acquiring an additional 2,437 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.4 %

NYSE:JNJ opened at $165.12 on Monday. The company’s fifty day moving average price is $162.98 and its 200-day moving average price is $154.69. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The firm has a market capitalization of $397.39 billion, a P/E ratio of 10.29, a PEG ratio of 2.65 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the prior year, the firm posted $2.66 earnings per share. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.00%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 30.92%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. TD Securities decreased their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Morgan Stanley increased their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Finally, TD Cowen decreased their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $175.93.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.